REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)

Completed

• Conditions: Huntington Disease; Huntington's Disease

• Registration Number: NCT01590589
• Lead Sponsor: European Huntington's Disease Network

Brief Summary

This is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers to:

* obtain natural history data on many HD mutation carriers and individuals who are part of an HD family

* relate phenotypical characteristics (genetic modifiers / wet and dry biomarkers)

* expedite identification and recruitment of participants for clinical trials

* develop and validate sensitive and reliable outcome measures for detecting onset and change over the natural course of premanifest and manifest HD which may also be potential outcome measures for use in future clinical trials and clinical care

* plan for future research studies

Detailed Description

REGISTRY integrates prospectively and systematically collected clinical research data (e.g. phenotypical clinical features, family history, demographical characteristics) with access to biological specimens (e.g. blood, urine) obtained from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g. spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation).

REGISTRY is an open-ended study and eligible subjects are assessed at annual study visits on the phenotypical characteristics of HD regardless of whether they display clinical symptoms and signs of the disease and of individuals who are part of an HD family (irrespective of their mutation carrier status). At each study visit, general clinical, motor function, behavior, cognitive, Health Economics, Quality of Life assessments are administered. In addition, participants are given the option to consent to the donation of biosamples for the purposes of mutation (CAG repeat length) testing and for research to identify biological modifiers and markers of HD. Biological specimens and phenotypical data are made available to qualified scientists whose projects are reviewed and approved by the Scientific and Bioethical Advisory Committee (SBAC) of EHDN. Successful applicants agree to accept the EHDN policies surrounding the use of the data/materials provided and publication of results (see data sharing and publication policies of EHDN, attached). Research projects should aim to advance scientific knowledge towards establishing clinically effective treatments that delay onset and/or slow the progression of the disease.

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2012-03-22
• Study First Submitted QC: 2012-05-02
• Study First Posted: 2012-05-03
• Primary Completion: 2017-06-30
• Study Completion: 2017-06-30
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-14
• Last Update Posted: 2017-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

The following individuals may be eligible to participate

• Individuals, confirmed HD mutation carrier
• Manifest HD, without mutation (CAG) testing
• HD family member at-risk, without CAG testing
• HD family member, non-HD mutation carrier
• REGISTRY-CONTROL participants: companion/individual without HD history
• REGISTRY-COMPANION (any of the above).

Exclusion Criteria

• Participants who are unable to understand the study protocol or unable to give informed consent, and have no legal representative.
• Participants with choreic movement disorder other than HD. (EHDN provides a Registry-like tool to record findings in patients affected with choreatic movement disorders other than HD under the label "Neuroacanthocytosis"; www.euro-hd.net/html/na/registry).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Phenotypical characteristics of HD	13 years	The goal of the project is to collect longitudinal data on the phenotypical characteristics of HD gene mutation carriers.

Trial Locations

Locations (140)

Universitätsklinik für Psychiatrie, Neuropsychiatrische Ambulanz; 🇦🇹 Graz, Austria

Universitätsklinik Innsbruck, Neurologie; 🇦🇹 Innsbruck, Austria

UCL-St Luc, Centre de génétique humaine; 🇧🇪 Brussels, Belgium

Institute of Pathology and Genetics (IPG); 🇧🇪 Gosselies, Belgium

Universitair Ziekenhuis Gasthuisberg, Dienst Neurologie; 🇧🇪 Leuven, Belgium

Fakultní nemocnice Olomouc, Neurologická klinika; 🇨🇿 Olomouc, Czechia

Centrum extrapyramidových onemocnění, Neurologická klinika, 1. LFUK; 🇨🇿 Praha 2, Czechia

University Hospital of Copenhagen - Rigshospitalet, Dept. of Neurology; 🇩🇰 Copenhagen Ø, Denmark

The Family Federation of Finland Väestöliitto, Department of Medical Genetics; 🇫🇮 Helsinki, Finland

Helsinki University Hospital, Dept. of Neurology; 🇫🇮 HUS, Finland

Scroll for more (130 remaining)